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Abstract 
 
Background: Cutaneous leishmaniasis is still a health problem in many rural and urban regions of Iran and drug 
resistance has emerged as a major impediment in the treatment of leishmaniasis. This study aims to determine 
the drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of Iran. 
 
Methods: Ninety seven samples were collected from ulcers of leishmaniasis patients from some endemic areas 
of Iran. The Giemsa stained samples were examined microscopically and cultured in NNN and RPMI 1640 medi-
ums for parasite detection. After DNA extraction, PCR was done by a pair of specific primers. For detection of 
mutation in DNA, first PCR products were electrophoresed on CSGE gel. The suspected samples were com-
pared by sequencing and RFLP results were demonstrated. Comparison of DNA derived from a wild type cell 
and mutant cell was undertaken by CSGE and sequencing methods. 
 
Results: Among 90 isolates (92.8%) examined for detection of mutation in gene with CSGE and RFLP, 10 
(11.1%) revealed a disorder in sequencing selection for unresponsive to drug. 
 
Conclusion: Drug resistance in cutaneous leishmaniasis to sodium stiboglocanat is probably due to a mutation 
in a genome. A field study is needed to determine the distribution of drug resistance and other gene mutations 
involved in unresponsiveness to drugs in leishmaniasis endemic areas of Iran. 
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Introduction 
 
Protozoan parasites are responsible for some of the 
most important and prevalent diseases of humans and 
domestic animals, threaten the lives of nearly one-
quarter of the human population. According to the 
World Health Organization (WHO) reports, a 42 fold 
amplify of leishmaniasis has occurred in the last 15 
years.
1 The pentavalent antimonial drugs of pento-
stam and glucantime are the first line treatments for 
leishmaniasis and resistance to these drugs is consid-
ered a severe clinical problem.
2 Glucantime resistance 
was reported in both Leishmaina tropica and Leish-
mania major.
3 The antimonites, which are the clinical 
drugs are frequently employed against leishmaniasis 
since 1920s, however, antimonites, have a narrow 
remedial window due to their toxicity and there are 
additional conditions which permit the resistance of 
Leishmania in the vertebrate host.  
In fact, WHO has pointed out that the occurrence 
of leishmaniasis has increased since the 1980s. This 
maybe due to the risk of co-infection with HIV and 
parasites causing visceral leishmaniasis.
4 
The lack of response of Leishmania to different 
drugs because of sub-optimal dosages is high and ris-
ing frequently.
5  Unresponsiveness to drug has 
emerged as a major problem in treatment of visceral 
leishmaniasis with more than 50% glucantime re-
sistance in India.
6 Several mechanisms probably are 
involved in such differences such as reduced drug 
uptake and faster drug metabolism. 
 
 
 
 
*Correspondence: Hossein Hooshyar, PhD, Department of Parasit-
ology, School of Medicine, Kashan University of Medical Sciences, 
Kashan, Iran. Tel: +98-361-5550021, Fax: +98-361-5551112, 
e-mail: hooshyar4@yahoo.com 
Received: June 12, 2011  Accepted: September 19, 2011 Alizadeh et al. 
 
WWW.ircmj.com Vol 13 December 2011  864
In unresponsiveness to drugs, the role of multidrug 
resistance (MDR)
 genes and their products were well 
established .In order to determine whether
 MDR gene 
amplification and over expression can be correlated 
with
  a multidrug resistance phenotype in parasitic 
protozoa such as Leishmania. Transfection experi-
ments using the MDR gene from L. donovani and L. 
enriettii have demonstrated that overexpression of 
this gene is responsible for the MDR phenotype ob-
served in the resistant parasites.
7 
Increased cholesterol content of plasma mem-
branes among others has recently been shown that P-
glycoprotein (PGP) over-expresses the cells transect-
ed with the MDR1 gene that is cross-resistant to the 
ALP imofosine.
8-10 PGP belongs to the ATP-binding 
cassette (ABC) super-family of transporters is an 
ATP-dependent pump that exports a wide range of 
hydrophobic drugs from the cell, decreasing their in-
tra-cellular concentration and preventing their cyto-
toxic activity, thus conferring a multi-drug resistance 
(MDR) phenotype during the treatment.
8,11 
The use of pentavalent antimonials such as meglu-
mine antimoniate (glucantime) is still the first study 
drug for treatment of leishmaniasis in Iran. Failure in 
treatment of and decrease in efficacy of glucantime were 
reported by some investigators in Iran.
3,12 The cure rate 
of this drug is 80-85% and recently Hadighi  et al. de-
scribed glucantime-resistant L. tropica isolates from 
cutaneous leishmaniasis (CL) patients in Iran.
13 
An understanding of the resistance mechanisms to 
sodium stibogluconate in leishmaniasis can help us to 
find strategies to pass up or conquer the problem be-
fore the wide spread use of sodium stiboglocanat for 
the treatment of Leishmania results in the appearance 
of clinical cases of resistance. The systematic analysis 
of drug resistance mutants is useful when trying to lin-
eate the drug target. The objective of this study was to 
determine of mutation in MDR gene presence in 
Leishmania isolated from responsive and unresponsive 
cases to glucantime in cutaneous leishmaniasis patients 
in Yazd, Mashhad and Kashan endemic provinces. 
 
 
Materials and Methods 
 
L. tropica and L. major were isolated from 97 skin le-
sions from both treated and untreated patients living in 
some endemic regions of Iran including Yazd, Mashhad 
and Kashan provinces. Some of these patients did not 
respond to glucantim for their skin ulcers. 
The amastigot form of Leishmania lesions was 
transferred to NNN medium culture with a liquid phase 
of normal saline including antibiotics (streptomycin and 
penicillin).The promastigote form of cloned L. tropica 
and L. major strains (wild type) were grown at 28°Ċ in 
RPMI 1640 customized medium supplemented with 
20% heat –inactivated fetal bovine serum (FBS). 
Isolates of cutaneous Leishmania were grown in 
RPMI1640 media for 3 weeks until the culture popu-
lations were in the log phase of growth. For DNA 
extraction, 50 ml of liquid phase of cultures centri-
fuged at 430 g for 20 min at 4°C and the resulting 
pellets were washed with phosphate-buffer saline 
(pH=7.4) and centrifuged once more at 1.730 g for 20 
min at 4˚C. Total nucleic acid was extracted using 
phenol/chloroform method.
14 
A set of oligonucleotid primer, Leish ReF2, (5 
′→3′ TCGACCGCGAGTGTCTCAGC) and leish 
ReR2 (5′→3′ TGGCATAGTGCGCAAAAGTG) 
were designed and used for PCR amplification. This 
primer amplified a 356 bp piece of the MDR of 
leishmaniasis (Accession NO L08091). The 30 µl 
reaction mixture contained (final concentration) 2 µl 
of DNA extract as template, 3 µl of 1X PCR buffer, 
1.5 µl of Mgc12, 0.5 µl of deoxynucleotide triphos-
phate(dNTP), 0.25 µl of Taq DNA polymerase(5U/µl; 
Gibco, BRL), 20.75 µl of dH2O and 2 µl of each of 
the forward and reverse primers. 
PCR reaction was carried out with 35 cycles, de-
naturation at 94°Ċ for 30 sec (3 min in cycle 1), an-
nealing at 56°C for 30 sec and elongation at 72°Ċ for 
30 sec (5 min in cycle 30). The PCR products were 
subjected to electrophoresis applying 1.5% agarose 
gel, stained by ethidium bromide and visualized un-
der a Tran's illuminator. 
This technique was developed as a result of a study 
in a rapid, non-radioactive-hetero duplex-based detec-
tion method for mutation screening. The method relies 
on the differential migration of DNA hetero-duplexes 
in comparison with homo duplexes during poly-acryl-
amide gel electrophoresis under gently denaturing 
conditions. For CSGE, 10 µl of PCR product was de-
naturized at 98°Ċ for 5 min and then re-annealing at 
68°Ċ for 30 sec. A total of 10 µl of product and 5 µl of 
loading buffer were separated by electrophoresis in 
10% poly-acryl-amide gel. Ethidium bromide staining 
and visualization under ultraviolet light determined 
those samples with peculiar banding patterns resulting 
from hetero-duplexes. 
This method was used for identification of mutation. 
In mutant isolates, the PCR product was digested in tow 
band whereas in mutation region, the PCR product   Drug resistance gene in leishmaniasis 
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remained undigested. Twenty µl of PCR amplified 
product was digested by SDU1 restriction enzyme for 
60 min at 37°Ċ. This enzyme was selected as DNAsis 
software. Then it was electrophoresed on 1% agarose 
gel, stained by ethidium bromide and the gels were ob-
served under ultraviolet (UV) trans-illuminator. 
 
 
Results 
 
A descriptive study of 97 samples of Leishmania 
which were collected from ulcers of patients, were 
observed microscopically and cultured in NNN and 
RPMI 1640 mediums. Genomic DNA’s were extract-
ed from promastigote stages according to Seabrook's 
methods (Figure 1). By molecular examination, 90 
(92.8%) samples successfully showed the desired 
band in PCR reaction and were examined for detec-
tion of mutation in the gene with CSGE and RFLP 
(Figure 2 and Figure 3). 
 
 
 
Fig. 1: DNA extraction with phenol chloroform method. 
 
 
Fig. 2: Detection of gene amplification. Ethidium 
bromide stained agarose gel containing molecular 
weight markers (line 1) and the 356 bp amplified band 
in line 2 and 3. 
    
 
Fig. 3: Mutation detection by use of restriction frag-
ment length polymorphisms (RFLPs). 
Line 1, 2, 5 digested product; Line 3 undigested 
product; Line4 100 bp ladder. 
 
 
Totally 10 samples In RFLP and CSGE presented 
mutation. At the end, 10 (11.1%) samples revealed a 
disorder in sequence selection for drug resistance 
(Figure 3). In resistance sample 6, samples were L. 
major and others were L. tropica. The mutant band 
were sent for sequencing and 2 patterns of nucleotide 
sequences of L. major were submitted to Genbank 
and are now available under the accession no. 
EU221237, EU221236. 
 
 
Discussion 
 
Leishmaniasis is still considered a health problem in 
many provinces of Iran
15-17 while drug resistance is 
the other problem in treatment of diseases. Multidrug 
resistance-like genes have now been identified in P. 
falciparum,  L. tarentolae and Entamoeba histolyti-
ca.
18 The aim of this study was to detect the mutations 
in MDR gene of agent of cutaneous leishmaniasis 
isolated from Iranian patients. 
Sb
5 is the drug of choice against Leishmania and 
resistance to it has unfortunately been slow to arise. 
This is consistent with the hypothesis that several mu-
tations are required for the emergence of resistance.
19 
Some investigators have selected Leishmania mutants 
for studies of resistance to antimonial drugs.
20 Several 
genes are involved in resistance which are consistent 
with the step by step selection procedure used to gen-
erate the mutants.
21 
As in the case of tumor cells, drug resistance in 
Leishmania  has been frequently associated with Alizadeh et al. 
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decreased cellular amassing of the drugs. Several hy-
potheses for decreased drug accumulation in resistant 
parasites have been proposed, including one analogous 
of the drug efflux pump model of drug resistant tumor 
cells, the increased expression of conserved type of 
protein called P-glycoprotein (p-gp) that has been one 
of the most consistent changes detected in drug-
resistant tumor cells.
22 The first MDR homologous 
gene discovered in Leishmania, LTPGPA, was an ex-
tra chromosomal circle (H-circle) amplified in a meth-
otrexate resistant L. tarentolae promastigote cell line. 
Since then, a group of genes belonging to the p-gp 
gene family and whose gene products conferred low 
levels of resistance to vinablastine arsenate and triva-
lent antimonial have been characterized in L .major. 
We showed that sodium stiboglocanat resistant was 
found in L. tropica and L. major in some endemic 
areas of Iran. The mutant isolates were identical to 
isolates with failure in therapy in clinic. It is neces-
sary to investigate on useful alternatives drugs for 
treatment of leishmaniasis in resistant patients. 
This study showed that unresponsiveness of cuta-
neus leishmaniasis to sodium stiboglocanat is due to a 
mutation in a genome. This mutation was seen in 
10% of sample isolates. We recommend a field study 
to determine the distribution of drug resistance and 
other gene mutations involved in unresponsiveness to 
drug in leishmaniasis endemic areas of Iran. 
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